Faiez Zannad Selected Research

Symporters

4/2024	Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
12/2023	Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
12/2022	Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
12/2021	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
1/2021	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
10/2019	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
10/2019	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
11/2017	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Faiez Zannad Research Topics

Disease

456	Heart Failure 05/2024 - 04/2003
91	Myocardial Infarction 04/2024 - 04/2003
52	Fibrosis (Cirrhosis) 03/2024 - 01/2005
50	Hypertension (High Blood Pressure) 01/2023 - 01/2000
41	Type 2 Diabetes Mellitus (MODY) 03/2024 - 01/2000
40	Cardiovascular Diseases (Cardiovascular Disease) 05/2024 - 01/2005
36	Inflammation (Inflammations) 05/2024 - 07/2007
33	Stroke (Strokes) 04/2024 - 05/2008
32	Left Ventricular Dysfunction 04/2022 - 04/2003
27	Atrial Fibrillation 05/2024 - 10/2006
27	Chronic Renal Insufficiency 03/2024 - 06/2010
26	Acute Coronary Syndrome 11/2023 - 10/2011
23	Hyperkalemia 01/2023 - 04/2003
20	Diabetes Mellitus 12/2022 - 07/2011
20	Systolic Heart Failure 01/2021 - 08/2003
19	Coronary Artery Disease (Coronary Atherosclerosis) 12/2023 - 09/2007
15	Body Weight (Weight, Body) 08/2023 - 05/2005
15	Hypotension (Low Blood Pressure) 01/2023 - 07/2011
14	Cardiomyopathies (Cardiomyopathy) 04/2024 - 01/2005
11	Chronic Kidney Failure (Chronic Renal Failure) 05/2024 - 05/2005
11	Heart Diseases (Heart Disease) 05/2024 - 03/2012
11	Respiratory Sounds (Crackle) 05/2024 - 04/2010
11	Atherosclerosis 01/2024 - 02/2004
11	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2023 - 08/2005
10	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2024 - 01/2000
10	Coronary Disease (Coronary Heart Disease) 11/2023 - 05/2008
9	Dyspnea (Shortness of Breath) 01/2024 - 03/2007
9	Albuminuria 12/2023 - 10/2003
9	Obesity 07/2023 - 07/2005
8	Neoplasms (Cancer) 01/2023 - 01/2011
8	Weight Loss (Weight Reduction) 01/2023 - 09/2002
7	ST Elevation Myocardial Infarction 10/2023 - 03/2014
7	Hypokalemia 01/2023 - 04/2003
7	Sudden Death 10/2022 - 01/2005
7	Hypertrophy 01/2022 - 10/2003
6	Renal Insufficiency (Renal Failure) 01/2021 - 11/2012
6	Disease Progression 01/2021 - 06/2006
6	Cardiac Arrhythmias (Arrythmia) 01/2021 - 07/2011

Drug/Important Bio-Agent (IBA)

97	Biomarkers (Surrogate Marker)IBA 04/2024 - 03/2006
70	empagliflozinIBA 04/2024 - 01/2017
60	Eplerenone (Inspra)FDA LinkGeneric 05/2024 - 04/2003
58	Mineralocorticoid Receptor AntagonistsIBA 05/2024 - 04/2007
52	Brain Natriuretic Peptide (Natrecor)FDA Link 04/2024 - 09/2007
42	Spironolactone (Aldactone)FDA LinkGeneric 05/2024 - 04/2011
34	pro-brain natriuretic peptide (1-76)IBA 05/2024 - 10/2009
32	Natriuretic PeptidesIBA 05/2024 - 09/2008
31	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 04/2023 - 10/2002
29	PotassiumIBA 01/2023 - 10/2003
29	Vasopressins (Vasopressin)IBA 01/2018 - 05/2005
28	Tolvaptan FDA Link 01/2018 - 05/2005
27	AldosteroneIBA 10/2023 - 04/2003
26	SodiumIBA 04/2024 - 03/2007
26	CreatinineIBA 01/2023 - 04/2010
23	CollagenIBA 05/2024 - 01/2005
22	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2023 - 01/2017
21	DiureticsIBA 05/2024 - 03/2007
21	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 07/2005
21	Angiotensin Receptor AntagonistsIBA 11/2022 - 11/2005
20	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2019
17	Valsartan (Vals)FDA Link 01/2023 - 11/2005
16	alogliptinIBA 07/2021 - 10/2011
15	C-Reactive ProteinIBA 05/2024 - 07/2007
15	Sodium-Glucose Transport ProteinsIBA 04/2024 - 01/2017
15	Neprilysin (Neutral Endopeptidase)IBA 01/2023 - 01/2017
14	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2023 - 01/2017
14	paragonIBA 01/2023 - 01/2017
13	AlbuminsIBA 01/2023 - 01/2000
13	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2023 - 03/2015
12	RivaroxabanIBA 12/2023 - 11/2013
12	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 01/2000
10	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2024 - 02/2004
10	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 08/2021 - 08/2013
10	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2020 - 10/2002
9	finerenoneIBA 05/2024 - 06/2012
9	Insulin (Novolin)FDA Link 05/2024 - 07/2005
9	omega-Chloroacetophenone (Mace)IBA 04/2024 - 01/2013
9	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2022 - 01/2005
8	SymportersIBA 04/2024 - 11/2017
8	Uric Acid (Urate)IBA 12/2023 - 12/2014
8	Procollagen Type IIBA 01/2023 - 09/2007
8	Galectin 3 (LGALS3)IBA 06/2022 - 01/2012
7	LipidsIBA 05/2024 - 05/2005
7	TroponinIBA 01/2024 - 01/2018
7	Troponin T (Troponin T1)IBA 12/2023 - 01/2021
7	procollagen type I carboxy terminal peptide (PICP)IBA 12/2023 - 01/2019
7	Collagen Type I (Type I Collagen)IBA 01/2023 - 05/2009
7	AngiotensinsIBA 09/2022 - 02/2009
7	Collagen Type III (Type III Collagen)IBA 01/2022 - 01/2005
7	aliskiren FDA Link 01/2018 - 01/2011
6	LDL CholesterolIBA 12/2023 - 04/2009
6	Growth Differentiation Factor 15IBA 11/2023 - 10/2017
6	CytokinesIBA 11/2023 - 06/2006
6	Losartan (Cozaar)FDA LinkGeneric 01/2023 - 12/2008
6	Hormones (Hormone)IBA 01/2023 - 10/2003
6	Peptides (Polypeptides)IBA 06/2022 - 01/2005

Therapy/Procedure

163	Therapeutics 05/2024 - 04/2003
11	Renal Dialysis (Hemodialysis) 05/2024 - 04/2009
9	Drug Therapy (Chemotherapy) 10/2023 - 01/2005
7	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 10/2019 - 09/2007
6	Patient Readmission 01/2023 - 04/2010